ptupb  (MedChemExpress)

Journal: Frontiers in Pharmacology

Article Title: Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation

doi: 10.3389/fphar.2019.01118

Figure Lengend Snippet: Effect of PTUPB, celecoxib and t -TUCB on allergen-induced airway cellular inflammation. (A) Outline of protocol for challenge with A. alternata and administration of PTUPB (dual sEH and COX-2 inhibitor), celecoxib (COX-2 inhibitor), t -TUCB (sEH inhibitor) or vehicle. i.n, intranasal. (B) Effect of inhibitors on survival of allergen-exposed mice. Alt, A. alternata . (C) Total cell counts in the BALF of control and A. alternata -challenged mice with or without administration of inhibitors. (D) H & E staining of lung tissue from mice identified in C. Representative image for each group is shown. Arrows indicate infiltrating inflammatory cells. (E) Concentration of EETs in lungs of control and A. alternata -challenged mice with or without administration of inhibitors. Scale bar, 50 µm in D. Data shown in C and E represent mean ± SEM. n = 6 mice for Alt/Celecoxib-30 group and 9-10 mice for all other groups in C and 5-6 mice/group in E. **p < 0.01 compared to PBS/PEG, # p < 0.05 and ## < 0.01 compared to Alt/PEG.

Article Snippet: A. alternata -challenged mice were administered daily with PTUPB, a sEH/COX-2 dual inhibitor, t -TUCB ( trans -4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]-cyclohexyloxy}-benzoic acid), a highly selective sEH inhibitor, or celecoxib, a selective COX-2 inhibitor (Sigma-Aldrich Corp., St. Louis, MO).

Techniques: Staining, Concentration Assay

Journal: Frontiers in Pharmacology

Article Title: Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation

doi: 10.3389/fphar.2019.01118

Figure Lengend Snippet: Airway eosinophil recruitment in allergen-challenged mice administered with PTUPB, celecoxib or t -TUCB. (A) Eosinophil, (B) macrophage, (C) neutrophil and (D) lymphocyte counts in the BALF of control and A. alternata -challenged mice with or without administration of PTUPB, celecoxib or t -TUCB. Data represent mean ± SEM. n = 6 mice for Alt/Celecoxib-30 group and 9-10 mice for all other groups. *p < 0.05 and ** < 0.01 compared to PBS/PEG, # p < 0.05 compared to Alt/PEG.

Article Snippet: A. alternata -challenged mice were administered daily with PTUPB, a sEH/COX-2 dual inhibitor, t -TUCB ( trans -4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]-cyclohexyloxy}-benzoic acid), a highly selective sEH inhibitor, or celecoxib, a selective COX-2 inhibitor (Sigma-Aldrich Corp., St. Louis, MO).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation

doi: 10.3389/fphar.2019.01118

Figure Lengend Snippet: PTUPB and t -TUCB inhibit eosinophil recruitment in the lung tissue of allergen-challenged mice. (A) Immunohistochemical staining for expression of eosinophil-specific MBP (stained dark brown, black arrows) in the lung tissue of control and A. alternata -challenged mice with or without administration of PTUPB, celecoxib or t -TUCB. A representative image for each group is shown. Scale bar, 50 µm. (B) Quantitation of infiltrated lung tissue eosinophils (i.e., MBP-positive cells) in mice described in A. (C) Percentage of eosinophils in the BM of mice identified in A based on cell morphology after Hema3 staining. Data represent mean ± SEM. n = 6-7 mice/group in B, 6 mice for Alt/Celecoxib-30 group and 7-9 mice for all other groups in C. **p <0.01 compared to PBS/PEG, # p < 0.05 compared to Alt/PEG. NS, not significant.

Article Snippet: A. alternata -challenged mice were administered daily with PTUPB, a sEH/COX-2 dual inhibitor, t -TUCB ( trans -4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]-cyclohexyloxy}-benzoic acid), a highly selective sEH inhibitor, or celecoxib, a selective COX-2 inhibitor (Sigma-Aldrich Corp., St. Louis, MO).

Techniques: Immunohistochemical staining, Staining, Expressing, Quantitation Assay

Journal: Frontiers in Pharmacology

Article Title: Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation

doi: 10.3389/fphar.2019.01118

Figure Lengend Snippet: Effect of PTUPB, celecoxib and t -TUCB on Th2 cytokines, eotaxins and IgE. (A) Th2 cytokine levels in BALF from control and A. alternata -challenged mice with or without administration of PTUPB, celecoxib or t -TUCB. (B) Eotaxin-1 and -2 levels in BALF, and (C) total IgE levels in the serum of mice identified in A. Data represent mean ± SEM. n = 5-7 mice per group. **p <0.01 compared to PBS/PEG, # p < 0.05 and ## p < 0.01 compared to Alt/PEG. NS, not significant.

Article Snippet: A. alternata -challenged mice were administered daily with PTUPB, a sEH/COX-2 dual inhibitor, t -TUCB ( trans -4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]-cyclohexyloxy}-benzoic acid), a highly selective sEH inhibitor, or celecoxib, a selective COX-2 inhibitor (Sigma-Aldrich Corp., St. Louis, MO).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation

doi: 10.3389/fphar.2019.01118

Figure Lengend Snippet: Effect of PTUPB, celecoxib and t -TUCB on allergen-induced changes in lung lipid mediators. Eicosanoid levels in control and A. alternata -challenged mice with or without administration of PTUPB, celecoxib or t -TUCB shown as fold change relative to unchallenged mice. Eicosanoids that were decreased by allergen exposure are shown in panel (A) and those that increased or remained unchanged are shown in panel (B) . n = 5-6 mice per group. *p < 0.05 compared to PBS/PEG, # p < 0.05 compared to Alt/PEG.

Article Snippet: A. alternata -challenged mice were administered daily with PTUPB, a sEH/COX-2 dual inhibitor, t -TUCB ( trans -4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]-cyclohexyloxy}-benzoic acid), a highly selective sEH inhibitor, or celecoxib, a selective COX-2 inhibitor (Sigma-Aldrich Corp., St. Louis, MO).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation

doi: 10.3389/fphar.2019.01118

Figure Lengend Snippet: Administration of PTUPB or t -TUCB attenuates allergen-induced mucus secretion and smooth muscle thickening but not AHR. (A) Measurement of pulmonary resistance ( RL ) following exposure to increasing concentrations of aerosolized methacholine (MCh) in mechanically ventilated control and A. alternata -challenged mice with or without administration of PTUPB or t -TUCB. (B and C) Airway mucus secretion based on PAS staining (stained dark-pink, black arrows) in control and A. alternata -challenged mice administered with vehicle or with PTUPB, celecoxib or t -TUCB and quantitation of PAS-positive area in the airways, respectively. (D and E) Airway smooth muscle thickening in mice described in B assessed by immunohistochemical staining for α-SMA expression and quantitation of α-SMA-positive area, respectively. Scale bar, 50 µm. Data represent mean ± SEM. n = 5-7 mice per group. ***p < 0.001 compared to PBS/PEG, ## p < 0.01 and ### < 0.001 compared to Alt/PEG.

Article Snippet: A. alternata -challenged mice were administered daily with PTUPB, a sEH/COX-2 dual inhibitor, t -TUCB ( trans -4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]-cyclohexyloxy}-benzoic acid), a highly selective sEH inhibitor, or celecoxib, a selective COX-2 inhibitor (Sigma-Aldrich Corp., St. Louis, MO).

Techniques: Staining, Quantitation Assay, Immunohistochemical staining, Expressing

Journal: Frontiers in Pharmacology

Article Title: Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation

doi: 10.3389/fphar.2019.01118

Figure Lengend Snippet: PTUPB, celecoxib and t -TUCB inhibit eosinophil migration. (A) Effect of pro-inflammatory mediators on expression of COX-2 in mouse eosinophils by qPCR. (B) Migration of eosinophils treated with PTUPB, celecoxib or t -TUCB at the indicated doses or vehicle alone towards eotaxin-1 in Transwell ® plates. Combined data (mean ± SEM) of three experiments in duplicate is shown. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 relative to untreated cells in A and DMSO in B.

Article Snippet: A. alternata -challenged mice were administered daily with PTUPB, a sEH/COX-2 dual inhibitor, t -TUCB ( trans -4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]-cyclohexyloxy}-benzoic acid), a highly selective sEH inhibitor, or celecoxib, a selective COX-2 inhibitor (Sigma-Aldrich Corp., St. Louis, MO).

Techniques: Migration, Expressing